A Phase 1/2 interventional study of AVI-4658 for Injection in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 2 sites in United Kingdom. Open to male participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2015-10-06.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1/2, and was the 2nd registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 5 Years to 15 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2009.
This study's enrollment of 19 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2009, is one of 5 in phase 1/2, and was the 1st registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
Primary outcome is safety, tolerability and dose selection for future studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
Drug: AVI-4658 for Injection
Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
Drug: AVI-4658 for Injection
Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
Drug: AVI-4658 for Injection
Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
Drug: AVI-4658 for Injection
Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
Drug: AVI-4658 for Injection
Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
Drug: AVI-4658 for Injection
AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
Also known as: Eteplirsen
Safety and Tolerability
Number of subjects with 1 or more Treatment Emergent Adverse Event that are possibly related to the investigational drug
Time frame: Baseline to 6 months
Treatment Emergent Adverse Events
Number of Patients with Treatment Emergent Adverse Events
Time frame: from Baseline to Follow up (27 weeks)
Pharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration
Standard Pharmacokinetic parameters estimated using non-compartmental modeling of plasma concentration data.
Time frame: Samples were taken: 30 minutes pre dose; and at 5 (±1), 15 (±2), 30 (±5), 60 (±5), and 90 (±5) minutes; and 2, 4, 6, 8, 12, and 24 hours (all ± 15 minutes) post dose at Weeks 1, 6, and 12
Efficacy of Eteplirsen Over 12 Weeks of Dosing
Efficacy was defined as an estimated change in the percentage of dystrophin positive fibers (assessed by IHC) at Week 14 from Baseline after 12 weekly doses of eterplirsen. This outcome measure represents the number of patients to show an increase in the percentage of dystrophin-positive fibers.
Time frame: Biopsies were taken at Baseline and Week 14
| Milestone | Cohort 1 - 0.5 mg/kg/wk | Cohort 2 - 1.0 mg/kg/wk | Cohort 3 - 2.0 mg/kg/wk | Cohort 4 - 4.0 mg/kg/wk | Cohort 5 - 10.0 mg/kg/wk | Cohort 6 - 20.0 mg/kg/wk |
|---|---|---|---|---|---|---|
| Started | 4 | 2 | 2 | 3 | 4 | 4 |
| Completed | 4 | 2 | 2 | 2 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
Number of subjects with 1 or more Treatment Emergent Adverse Event that are possibly related to the investigational drug
| participants | Open Label Treatment Arm |
|---|---|
| Safety and Tolerability | 14 |
Standard Pharmacokinetic parameters estimated using non-compartmental modeling of plasma concentration data.
| ng/mL | Open Label Treatment Arm |
|---|---|
| Pharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration | 39000 ± 16900 |
Efficacy was defined as an estimated change in the percentage of dystrophin positive fibers (assessed by IHC) at Week 14 from Baseline after 12 weekly doses of eterplirsen. This outcome measure represents the number of patients to show an increase in the percentage of dystrophin-positive fibers.
| participants | Open Label Treatment Arm |
|---|---|
| Efficacy of Eteplirsen Over 12 Weeks of Dosing | 11 |
Number of Patients with Treatment Emergent Adverse Events
| participants | Open Label Treatment Arm |
|---|---|
| Treatment Emergent Adverse Events | 19 |
Adverse events that occurred in \>15% of overall patient population across dose level arms.
| Events | Cohort 1 - 0.5 mg/kg/wk | Cohort 2 - 1.0 mg/kg/wk | Cohort 3 - 2.0 mg/kg/wk | Cohort 4 - 4.0 mg/kg/wk | Cohort 5 - 10.0 mg/kg/wk | Cohort 6 - 20.0 mg/kg/wk |
|---|---|---|---|---|---|---|
| Cardiomyopathy | 0 | 0 | 0 | 1 | 0 | 2 |
| Tachycardia | 0 | 0 | 0 | 1 | 0 | 2 |
| Abdominal Pain | 0 | 1 | 0 | 1 | 1 | 0 |
| Nausea | 0 | 0 | 1 | 1 | 0 | 1 |
| Vomiting | 0 | 0 | 1 | 1 | 1 | 0 |
| Influenza like illness | 0 | 0 | 2 | 0 | 1 | 0 |
| Rhinitis | 1 | 0 | 0 | 1 | 4 | 1 |
| Upper respiratory tract infection | 2 | 1 | 0 | 1 | 2 | 2 |
| Fall | 2 | 0 | 0 | 2 | 0 | 1 |
| Arthralgia | 1 | 0 | 1 | 1 | 0 | 0 |
| Back Pain | 1 | 0 | 1 | 2 | 2 | 1 |
| Myalgia | 1 | 1 | 1 | 0 | 1 | 0 |
| Dizziness | 0 | 0 | 1 | 1 | 0 | 1 |
| Headache | 2 | 1 | 2 | 0 | 2 | 1 |
Collected over Adverse Event data for this study was collected from Baseline to Follow-up (27 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - 0.5 mg/kg/wk | — | 0/4 (0%) | 4/4 (100%) |
| Cohort 2 - 1.0 mg/kg/wk | — | 0/2 (0%) | 2/2 (100%) |
| Cohort 3 - 2.0 mg/kg/wk | — | 1/2 (50%) | 2/2 (100%) |
| Cohort 4 - 4.0 mg/kg/wk | — | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 5 - 10.0 mg/kg/wk | — | 0/4 (0%) | 4/4 (100%) |
| Cohort 6 - 20.0 mg/kg/wk | — | 0/4 (0%) | 4/4 (100%) |
| Event | Cohort 1 - 0.5 mg/kg/wk | Cohort 2 - 1.0 mg/kg/wk | Cohort 3 - 2.0 mg/kg/wk | Cohort 4 - 4.0 mg/kg/wk | Cohort 5 - 10.0 mg/kg/wk | Cohort 6 - 20.0 mg/kg/wk |
|---|---|---|---|---|---|---|
| Post-Operative Nausea and VomitingGastrointestinal disorders | 0/4 | 0/2 | 1/2 | 0/3 | 0/4 | 0/4 |
| Fracture of Left Medial MalleolusMusculoskeletal and connective tissue disorders | 0/4 | 0/2 | 0/2 | 1/3 | 0/4 | 0/4 |
| Event | Cohort 1 - 0.5 mg/kg/wk | Cohort 2 - 1.0 mg/kg/wk | Cohort 3 - 2.0 mg/kg/wk | Cohort 4 - 4.0 mg/kg/wk | Cohort 5 - 10.0 mg/kg/wk | Cohort 6 - 20.0 mg/kg/wk |
|---|---|---|---|---|---|---|
| RhinitisInfections and infestations | 1/4 | 0/2 | 0/2 | 1/3 | 4/4 | 1/4 |
| HeadacheNervous system disorders | 2/4 | 1/2 | 2/2 | 0/3 | 2/4 | 1/4 |
| Influenza like illnessGeneral disorders | 0/4 | 0/2 | 2/2 | 0/3 | 1/4 | 0/4 |
| FallInjury, poisoning and procedural complications | 2/4 | 0/2 | 0/2 | 2/3 | 0/4 | 1/4 |
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 0/2 | 1/2 | 2/3 | 2/4 | 1/4 |
| Upper respiratory tract infectionInfections and infestations | 2/4 | 1/2 | 0/2 | 1/3 | 2/4 | 2/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/4 | 1/2 | 1/2 | 0/3 | 1/4 | 0/4 |
| TachycardiaCardiac disorders | 0/4 | 0/2 | 0/2 | 1/3 | 0/4 | 2/4 |
| NauseaGastrointestinal disorders | 0/4 | 0/2 | 1/2 | 1/3 | 0/4 | 1/4 |
| VomitingGastrointestinal disorders | 0/4 | 0/2 | 1/2 | 1/3 | 1/4 | 0/4 |
| Age, Continuous(years) | Cohort 1 - 0.5mg/kg/wk | Cohort 2 - 1.0mg/kg/wk | Cohort 3 - 2.0mg/kg/wk | Cohort 4 - 4.0mg/kg/wk | Cohort 5 - 10.0mg/kg/wk | Cohort 6 - 20.0mg/kg/wk | Total |
|---|---|---|---|---|---|---|---|
| Mean | 8.3 ± 0.50 | 6.0 ± 0.0 | 11.0 ± 2.83 | 9.7 ± 0.58 | 8.8 ± 2.75 | 8.8 ± 1.26 | 8.7 ± 1.91 |
| Sex: Female, Male(Participants) | Cohort 1 - 0.5mg/kg/wk | Cohort 2 - 1.0mg/kg/wk | Cohort 3 - 2.0mg/kg/wk | Cohort 4 - 4.0mg/kg/wk | Cohort 5 - 10.0mg/kg/wk | Cohort 6 - 20.0mg/kg/wk | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 4 | 2 | 2 | 3 | 4 | 4 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - 0.5mg/kg/wk | Cohort 2 - 1.0mg/kg/wk | Cohort 3 - 2.0mg/kg/wk | Cohort 4 - 4.0mg/kg/wk | Cohort 5 - 10.0mg/kg/wk | Cohort 6 - 20.0mg/kg/wk | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 2 | 2 | 3 | 4 | 4 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 - 0.5mg/kg/wk | Cohort 2 - 1.0mg/kg/wk | Cohort 3 - 2.0mg/kg/wk | Cohort 4 - 4.0mg/kg/wk | Cohort 5 - 10.0mg/kg/wk | Cohort 6 - 20.0mg/kg/wk | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 1 | 2 | 3 | 4 | 4 | 18 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Body Weight(kilograms) | Cohort 1 - 0.5mg/kg/wk | Cohort 2 - 1.0mg/kg/wk | Cohort 3 - 2.0mg/kg/wk | Cohort 4 - 4.0mg/kg/wk | Cohort 5 - 10.0mg/kg/wk | Cohort 6 - 20.0mg/kg/wk | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33 ± 4.09 | 23.7 ± 3.46 | 42.6 ± 6.36 | 40.1 ± 19.00 | 34.6 ± 14.01 | 33.0 ± 8.71 | 34.5 ± 10.84 |
| Height(centimeters) | Cohort 1 - 0.5mg/kg/wk | Cohort 2 - 1.0mg/kg/wk | Cohort 3 - 2.0mg/kg/wk | Cohort 4 - 4.0mg/kg/wk | Cohort 5 - 10.0mg/kg/wk | Cohort 6 - 20.0mg/kg/wk | Total |
|---|---|---|---|---|---|---|---|
| Mean | 127.3 ± 5.05 | 110.7 ± 4.45 | 126.9 ± 5.09 | 126.9 ± 14.40 | 123.7 ± 10.04 | 126.5 ± 7.18 | 124.5 ± 8.99 |
The record gives a start of Jan 2009, a primary completion of Jun 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →